Skip to main content
SpringerLink
Log in

Conflict of opinion -- is PROWESS real progress?

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mackenzie AF (2005) Activated protein C: do more survive? Intensive Care Med 31:1624–1626

    Article  PubMed  Google Scholar 

  2. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes JM (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE. Crit Care Med 33:2266–2277

    Article  PubMed  CAS  Google Scholar 

  3. Press Release EMEA 21 April 2005 Meeting of the Committee for Medicinal Products for Human Use (CHMP) www.emea.eu.int/htms/hotpress/h13844405.htm Accessed 25 January 2006

  4. NICE Technology Appraisals: Sepsis (severe) drotrecogin – (No 84) http://www.nice.org.uk/page.aspx?o=221104 Accessed 25 January 2006

  5. Summary of product characteristics – Xigris http://www.emea.eu.int/humandocs/Humans/EPAR/xigris/Xigris.htm Accessed 25 January 2006

  6. Smith R (2005) Medical journals are an extension of the marketing arm of pharmaceutical companies. PloS Med 2(5): e138 http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10%2E1371%2Fjournal%2Epmed%2E0020138 Accessed 25 January 2006

  7. Dellinger RP, Carlet J, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM for the Surviving Sepsis Campaign Management Guidelines Committee (2004) Crit Care Med 32:858–873

  8. Angus DC, Laterre PF, Helterbrand J, Ball DE, Garg R, Bernard GR (2002) The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis (abstract) Chest 122 (4) [Suppl]

  9. Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR for the PROWESS Investigators (2004) The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 32:2199–2206

    Article  PubMed  CAS  Google Scholar 

  10. Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC (2004) Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 32:2207–2218

    PubMed  Google Scholar 

  11. FDA Clinical Review Drotrecogin Alfa (activated) [Recombinant Human Activated Protein C (rhAPC)] xigris bla# 125029/0. Approved:November 21, 2001 www.fda.gov/cder/biologics/review/droteli112101r1.htm (Accessed 25 January 2006)

  12. Transcript of the FDA Anti-infective Drug Advisory Committee meeting, 16 October 2001. www.fda.gov/ohrms/dockets/ac/cder01.htm (page 110 Word version – accessed 25 January 2006

  13. The SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350: 2247–2256

    Google Scholar 

  14. Farmer JC (2005) Drotrecogin alfa (activated) treatment in severe sepsis: A “journal club” review of the global ENHANCE trial. Crit Care Med 33:2428–2431

    Article  PubMed  Google Scholar 

  15. Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma B. L, François B, Guy J. S, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback B. G, Macias W. L. The Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341

    Article  PubMed  CAS  Google Scholar 

  16. Parrillo JE (2005) Severe sepsis and therapy with activated protein C. N Engl J Med 353: 1398–1400

    Google Scholar 

  17. Eichacker PQ, Danner RL, Suffrendini AF, Cui X, Natanson C (2005) Reassessing recombinant activated protein C for sepsis: Time for a new randomized controlled trial. Crit Care Med 33:2426–2428

    Article  PubMed  Google Scholar 

  18. Intensive Care Monitor – A current awareness journal for intensivists. Volume 12 No.6 (November/December 2005 – page 113). ICM Index number 12/085

  19. Drotrecogin alfa (activated) for severe sepsis (2006) DTB Vol 44 No 1

  20. Slutsky AS, Lavery JV (2004) Data safety and monitoring boards. N Engl J Med 350:1143–1147

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Intensive Care Unit, Queen Margaret Hospital, Whitefield Road, KY12 0SU, Dunfermline, Scotland, UK

    Alasdair F. Mackenzie

Authors
  1. Alasdair F. Mackenzie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alasdair F. Mackenzie.

Additional information

This reply refers to articles available at http://dx.doi.org/10.1007/s00134-006-0086-9; http://dx.doi.org/10.1007/s00134-006-0087-8; http://dx.doi.org/10.1007/s00134-006-0088-7; http://dx.doi.org/10.1007/s00134-006-0089-6

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mackenzie, A.F. Conflict of opinion -- is PROWESS real progress?. Intensive Care Med 32, 610–612 (2006). https://doi.org/10.1007/s00134-006-0090-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-006-0090-0

Keywords

Search

Navigation